+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Metabolic Acidosis - Pipeline Insight, 2024 - Product Thumbnail Image

Metabolic Acidosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Phenylketonuria - Pipeline Insight, 2024 - Product Thumbnail Image

Phenylketonuria - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 110 Pages
  • Global
From
From
Male Hypogonadism - Pipeline Insight, 2024 - Product Thumbnail Image

Male Hypogonadism - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Pancreatic Endocrine Tumor - Pipeline Insight, 2024 - Product Thumbnail Image

Pancreatic Endocrine Tumor - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Pancreatitis - Pipeline Insight, 2024 - Product Thumbnail Image

Pancreatitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
Idiopathic Short Stature - Pipeline Insight, 2024 - Product Thumbnail Image

Idiopathic Short Stature - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Exocrine Pancreatic Insufficiency - Pipeline Insight, 2024 - Product Thumbnail Image

Exocrine Pancreatic Insufficiency - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Porphyria - Pipeline Insight, 2024 - Product Thumbnail Image

Porphyria - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 65 Pages
  • Global
From
Secondary Hyperparathyroidism - Pipeline Insight, 2024 - Product Thumbnail Image

Secondary Hyperparathyroidism - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Insulin Resistance - Pipeline Insight, 2024 - Product Thumbnail Image

Insulin Resistance - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Hyperparathyroidism - Pipeline Insight, 2024 - Product Thumbnail Image

Hyperparathyroidism - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Hyperphosphatemia - Pipeline Insight, 2024 - Product Thumbnail Image

Hyperphosphatemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Acromegaly - Pipeline Insight, 2024 - Product Thumbnail Image

Acromegaly - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
Diabetic Gastroparesis - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetic Gastroparesis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Turner Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Turner Syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Methylmalonic acidaemia - Pipeline Insight, 2024 - Product Thumbnail Image

Methylmalonic acidaemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more